The gut-liver axis in fatty liver disease: role played by natural products

被引:4
|
作者
Ming, Zhu [1 ,2 ]
Ruishi, Xie [1 ,2 ]
Linyi, Xu [1 ,2 ]
Yonggang, Yang [3 ]
Haoming, Luo [1 ,2 ]
Xintian, Lan [1 ,2 ]
机构
[1] Changchun Univ Chinese Med, Changchun, Peoples R China
[2] Changchun Univ Chinese Med, Sch Pharm, Changchun, Peoples R China
[3] Baicheng Med Coll, Baicheng 137000, Peoples R China
基金
中国国家自然科学基金;
关键词
gut-liver axis; NAFLD; ALD; natural products; plant metabolites; MICROBIOTA; INJURY; MICE; MECHANISMS; DYSBIOSIS; CIRRHOSIS; BARRIER; PAEONOL; ACIDS;
D O I
10.3389/fphar.2024.1365294
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fatty liver disease, a condition characterized by fatty degeneration of the liver, mainly classified as non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD), has become a leading cause of cirrhosis, liver cancer and death. The gut-liver axis is the bidirectional relationship between the gut and its microbiota and its liver. The liver can communicate with the gut through the bile ducts, while the portal vein transports the products of the gut flora to the liver. The intestinal flora and its metabolites directly and indirectly regulate hepatic gene expression, leading to an imbalance in the gut-liver axis and thus contributing to the development of liver disease. Utilizing natural products for the prevention and treatment of various metabolic diseases is a prevalent practice, and it is anticipated to represent the forthcoming trend in the development of drugs for combating NAFLD/ALD. This paper discusses the mechanism of the enterohepatic axis in fatty liver, summarizes the important role of plant metabolites in natural products in fatty liver treatment by regulating the enterohepatic axis, and provides a theoretical basis for the subsequent development of new drugs and clinical research.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] The gut-liver axis in nonalcoholic fatty liver disease: molecular mechanisms and new targets
    Schneider, Kai Markus
    Trautwein, Christian
    GASTROENTEROLOGE, 2020, 15 (02): : 112 - 122
  • [2] Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis
    Han, Hui
    Jiang, Yi
    Wang, Mengyu
    Melaku, Mebratu
    Liu, Lei
    Zhao, Yong
    Everaert, Nadia
    Yi, Bao
    Zhang, Hongfu
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2023, 63 (12) : 1689 - 1706
  • [3] Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease
    Poeta, Marco
    Pierri, Luca
    Vajro, Pietro
    CHILDREN-BASEL, 2017, 4 (08):
  • [4] Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis: Exploring an Undernutrition Perspective
    Bauer, Kylynda C.
    Littlejohn, Paula T.
    Ayala, Victoria
    Creus-Cuadros, Anna
    Finlay, B. Brett
    GASTROENTEROLOGY, 2022, 162 (07) : 1858 - +
  • [5] Viral Liver Disease and Intestinal Gut-Liver Axis
    Kouroumalis, Elias
    Tsomidis, Ioannis
    Voumvouraki, Argyro
    GASTROINTESTINAL DISORDERS, 2024, 6 (01): : 64 - 93
  • [6] Gut-Liver Axis in Alcoholic Liver Disease
    Szabo, Gyongyi
    GASTROENTEROLOGY, 2015, 148 (01) : 30 - 36
  • [7] Targeting the gut-liver axis in liver disease
    Wiest, Reiner
    Albillos, Agustin
    Trauner, Michael
    Bajaj, Jasmohan S.
    Jalan, Rajiv
    JOURNAL OF HEPATOLOGY, 2017, 67 (05) : 1084 - 1103
  • [8] Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease
    Giulia Paolella
    Claudia Mandato
    Luca Pierri
    Marco Poeta
    Martina Di Stasi
    Pietro Vajro
    World Journal of Gastroenterology, 2014, 20 (42) : 15518 - 15531
  • [9] Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease
    Paolella, Giulia
    Mandato, Claudia
    Pierri, Luca
    Poeta, Marco
    Di Stasi, Martina
    Vajro, Pietro
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (42) : 15518 - 15531
  • [10] Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease
    Xue, Rui
    Su, Lianyong
    Lai, Shengyi
    Wang, Yanyan
    Zhao, Derrick
    Fan, Jiangao
    Chen, Weidong
    Hylemon, Phillip B.
    Zhou, Huiping
    CELLS, 2021, 10 (11)